The objectives of this study were to evaluate the endometrial histology and cervical cytology of users of two contraceptive implants releasing etonogestrel/3-keto-desogestrel (Implanon®) and levonorgestrel (Norplant®) in West Midlands (UK) users. A 2-year prospective randomized design was used to study 60 implant users. Endometrial histology and cervical cytology were compared before insertion and after 12 and 24 months. At the end of 12 months, the majority of samples were inactive/weakly proliferative in both groups. At the end of 24 months, this remained unchanged in the Implanon® group whereas the pattern was more diverse in the Norplant® group. Endometrial thickness was significantly reduced in both groups during treatment. Cervical cytology remained unchanged. It is concluded that, after 2 years, there was no evidence of an increasing risk of endometrial hyperplasia, endometrial carcinoma, cervical intra-epithelial neoplasia or cervical carcinoma in either of the two groups of implant users.
Introduction
Subdermal contraceptive implants are a further approach to meet the worldwide need for more effective and acceptable birth control. They provide long-acting, highly efficient and immediately reversible contraception (Mascarenhas, 1994) by achieving low, stable concentrations of synthetic progestogens for several years and require little user compliance, therefore achieving user failure rates that are similar to the method failure rate (Diaz et al., 1982; Sivin et al., 1983) .
Norplant® is a six-capsule implant system releasing levonorgestrel and is effective for 5 years. It has been registered in 60 countries and has been used by some 6 million women worldwide (Norplant® consensus statement, 1998) . Finland was the first country to introduce it in 1983, and the USA introduced it in December 1990 and the UK in October 1993. Clinical studies have involved over 55 000 women and have shown it to be one of the most effective methods of contraception that is currently available: the 5-year cumulative pregnancy rate is approximately 1 per 100 users (0.26 per 100 woman years) (Norplant® Consensus Statement, 1998) . More recently, Norplant® has been modified by using lower density tubing as the method failure rate with this tubing is lower, probably because a greater daily release of levonorgestrel is known to occur (Sivin, 1988) . Insertion by trained practitioners takes on average 5-10 min and removal about 20-30 min (Population Council, 1992) . Norplant® II is a two-rod implant system releasing levonorgestrel and is effective for 3 years. It was approved by the USA Food and Drug Administration in 1996.
Implanon® is a single-rod implant system releasing etonogestrel and is effective for 3 years (Makarainen et al., 1998) . Like Norplant® II it is a newer implant system and has completed phase III clinical trials; worldwide experience with 2046 implants (59 800 cycles of use) has not revealed a single pregnancy (95% confidence interval, 0.00-0.08) (NV Organon, 1997) . Insertion by trained practitioners in Birmingham took on average 2 min and removal 3 min (NV Organon, 1997) . It is envisaged that Implanon® will be marketed in the UK in a few years.
Implants share common disadvantages: mainly the dependence on healthcare providers for insertion, removal and counselling. They also have progestogen-related side-effects, of which the most common is irregular menstrual bleeding caused by the erratic shedding of hypotrophic endometrium. This makes counselling an essential part of the method. The bleeding patterns produced, however, are mostly acceptable.
The Academic Department at Birmingham has the largest clinical experience with contraceptive implants in the UK: in 1993, over 250 implants were inserted of which 110 are in clinical trials comparing Norplant® with Implanon®
Materials and methods
The first 60 volunteers participating in an open, prospective, randomized trial of Norplant® versus Implanon® assessing efficacy, safety and acceptability were assessed in detail with regard to endometrial histology and cervical cytology after 12 and 24 months. This was part of a two-centre randomized study of 80 volunteers taking part in a phase III contraceptive study. The size of the study was chosen following World Health Organization (WHO) recommendations for this type of investigation (WHO, 1987) . Only volunteers with documented regular menstrual cycles (24-35 days) and good general health were accepted into the study, and the screening endometrial biopsy and cervical smear were taken during the mid-luteal phase in the cycle prior to implant insertion and 1 year and 2 years later (15-27 months), respectively. Randomization was performed in blocks of four using a computer-generated list. Subject characteristics were similar in both groups (Table I ). All volunteers gave written informed consent to participate in the study, which received Ethics Committee approval. Endometrial sampling was performed by Pipelle de Cornier and the samples were transported in formalin (4% formaldehyde in phosphate-buffered saline) and mounted in wax sections of 4 µ each. They were examined subsequently by the staff of the Birmingham Maternity Hospital Academic Department's histopathology unit. They were categorized according to the criteria shown in Table II .
Endometrial thickness was assessed by 3-monthly transvaginal ultrasound scans. For screening and post-treatment assessments, on average four measurements were taken per subject; the individual maximum endometrial thickness per assessment was reported in the results.
Cervical smears were taken using an Ayres spatula and subsequently were fixed with 96% ethyl alcohol. They were subsequently stained 3058 following the Papanicolaou technique and were examined by the staff of the Birmingham Maternity Hospital Academic Department's cytology screening unit.
Results
At admission to the study, there was no significant difference between the mean age, height, weight, body mass indices, and systolic and diastolic blood pressures between the two groups ( Table I ). All acceptors were Caucasian, aged between 18 to 40 years, had regular menstrual cycles (24-35 days) and weighed less than 75 kg. The majority of our acceptors belonged to socio-economic class I or II and had a similar duration of education. Table II shows the categories of endometrial histology. Table III shows comparative endometrial histology patterns at screening, after 12 and 24 months respectively. At the end of 12 months, the majority of samples were either inactive/weakly proliferative in both groups. At the end of 24 months, this remained unchanged in the Implanon® group, whereas the pattern was more diverse in the Norplant® group.
Endometrial histology

Endometrial thickness
Endometrial thickness was significantly reduced in both groups during treatment (Table IV) . The mean and median thickness remained Ͻ4 mm at 12 and 24 months in the Implanon® group, whereas the mean and median thickness were slightly greater in the Norplant® group.
Cervical cytology
There was no change in cervical cytology after 12 and 24 months, all users having a normal smear at study entry.
Discussion
All 60 volunteers had a mid-luteal phase endometrial sampling using a Pipelle de Cornier. As all these volunteers had regular cycles (menses occurring every 24-35 days) as part of the inclusion criteria, this biopsy was timed at 7 days prior to the onset of the next expected menstruation. In spite of this, it is surprising to note that six out of 30 biopsies (20%) in the Implanon® group and seven out of 30 biopsies (23%) in the Norplant® group were described as proliferative or menstrual at histological diagnosis. This suggests that women's subjective recall of the date of their last normal period may not be accurate in about a quarter to a fifth of cases. At the end of 12 and 24 months, however, it is reassuring to note that the majority of samples were inactive/weakly proliferative in the Implanon® group. This contrasts with the Norplant® group in the sense that, after 24 months, there was evidence of proliferative-phase endometrium. This was probably due to a differential progestogen effect and has not been reported previously. In both groups, there was no evidence of atrophic endometrium.
Perhaps the earliest report that endometrial hyperplasia could be reversed by progestogen therapy came from Kistner Endometrial histology and contraceptive implants Whitehead et al. (1981 Whitehead et al. ( , 1982 provided a biochemical explanation for the effects of progestogens on the oestrogenprimed endometrium. These studies offer indirect evidence that progestogens exert a chemopreventive action on the endometrium. Data on 187 cases and 1320 controls from the Centers for Disease Control Cancer and Steroid Hormone Studies (Centers for Disease Control, 1983) showed that non-users of oral contraceptives were twice as likely to develop endometrial cancer as combined oral contraceptive users. These results were consistent with data from two large prospective British studies (Kay, 1980) and studies by Hulka et al. (1982) . In the 3059 latter study, the degree of protection against endometrial cancer was greater with oral contraceptives containing greater progestational activity, thus providing additional evidence of a chemopreventive effect of progestogens. However, for every 100 000 women in the USA who have never used oral contraceptives, the number developing endometrial cancer between the ages of 20-54 years is estimated to be 438 compared with 241 who had used oral contraceptives for 8 years (Schlesselmann, 1995) . Thus, in order to design a study with sufficient power to detect a difference between two groups, one would need 250 000 women in each arm, which is clearly impractical. Comparative studies were therefore performed along WHO guidelines, which require randomizedgroup comparisons of at least 40 in each group for the entire duration of the effect of the contraceptive steroid (WHO, 1987) .
Out-patient endometrial sampling using a Pipelle sampler (Cornier, 1984) has been shown to be an acceptable technique, comparing favourably with the Vabra aspirator (Kaunitz et al., 1988; Eddowes et al., 1990) and with the Novak curette (Silver et al., 1991; Stovall et al., 1991) . This technique seems to be as accurate as a traditional dilatation and curettage with regard to histological diagnoses (Fothergill et al., 1992) .
Findings in this study are in line with international experience with Norplant®, which suggests that constant low concentrations of levonorgestrel suppress endometrial growth (Croxatto et al., 1984) . A cut-off of 4-mm endometrial thickness has been proposed whereby invasive sampling can be avoided, as endometrial malignancy has not been reported at histological biopsy below this thickness (Varner et al., 1991) . More recently, Rogers (1996) reported that the endometrium of Norplant® users was always thinner than that of non-users, with a varied histology that usually included a basalis-type appearance, signs of haemorrhage and some dilated and congested subepithelial vessels. Others have suggested that, after 3-12 months Norplant® exposure, nearly 50% of women have an endometrium too thin to sample . Endometrial microvascular density is increased in Norplant® users (Hickey et al., 1996) . However, there was no difference in endometrial angiogenic activity between users with and without bleeding problems (Subakir et al., 1996) . Furthermore, in contrast to previous findings of an increase in immunoreactive progesterone-receptor protein in Norplant® user endometrium, progesterone receptor mRNA concentrations are reduced (Lau et al. 1996) .
It was also reassuring to note that no significant change had occurred in cervical cytology. Volunteers in both groups had to have a normal cytological smear as an entry requirement to the trial and no change in cervical cytology was noted at the end of 1 and 2 years of use. In another study, an insignificant increase in the incidence of abnormal smears after treatment with Norplant® implants (2.8% versus 1.3%) was reported as compared with the pretreatment incidence (Misra et al., 1995) , whereas there was a significantly increased incidence of abnormal smears in the group with a copper intrauterine device (4.9% versus 2.1%).
This study shows that, after a period of 2 years, there is no evidence of an increasing risk of endometrial hyperplasia, endometrial carcinoma, cervical intra-epithelial neoplasia or cervical carcinoma in either of the two groups of implant users that were studied. However, in view of the study size and the subjects' social class other findings would have been unlikely.
